Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC37,70,71”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“Several mechanisms of resistance to antiangiogenic therapy have been proposed thus far (9, 33).”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840 · cited 1×
“Total collagen content was determined by measuring hydroxyproline content of the hydrolysate samples (76).”
MethodDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 2×
“Our recent studies showed that HA impairs vascular function and drug delivery into the tumor in animal models of pancreatic and prostate cancers (12, 15, 43, 44).”
BackgroundHyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Self-citationMacrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationRole of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Self-citationOxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159 · cited 1×
“Besides induction of the epithelial-to-mesenchymal program that favors an invasive and metastatic tumor cell phenotype (34), hypoxia is thought to select for tumor cells with cancer stem cell properties that might further mediate resistance to cytotoxics, as well as favoring an immunosuppressivemicroenvironment by red…”
BackgroundSherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 3×
“For perfusion measurement, Hoechst 33342 (Sigma) was administered by portal infusion 5 min before tumor tissue collection (31).”
BackgroundMethodInfluentialSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Self-citationHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976 · cited 1×
“Increased fibrosis is another effect of hypoxia on themicroenvironment of tissues and is dependent on hypoxia-inducible factor 1a (40).”
BackgroundCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 5×
“Solid stress was determined using a recently proposedmethod (6).”
BackgroundMethodInfluentialSelf-citationBiosynthetic response of cartilage explants to dynamic compression
Sah, R. L. ‐., Kim, Y., Doong, J. H., Grodzinsky, A. J., Plass, A. H. K., & Sandy, J. D. (1989) · Journal of Orthopaedic Research · doi:10.1002/jor.1100070502 · Cited by 875 · cited 2×
“Biochemical assays sGAG content in finely dispersed tissues was determined by the Dimethylmethylene Blue Assay (DMMB) (75).”
MethodSelf-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“In line with these data, we also found an increased recruitment of immunosuppressive MDSCs after anti-VEGF therapy (41, 42).”
BackgroundStrategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Self-citationKarlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 1×
“8, 360ra135 (2016) 12 October 2016 Angiotensin II receptor 1 deletion does not affect HA expression in mCRC after anti-VEGF therapy The angiotensin II receptor 1 (AT1) signaling pathway is a relevant mediator of ECM deposition through transforming growth factor–b (TGF-b) activation and a potential target to decrease t…”
BackgroundSelf-citationYu, Q., & Stamenkovic, I. (1999) · Genes & Development · doi:10.1101/gad.13.1.35 · Cited by 713
Origins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Whatcott, C. J., Diep, C. H., Jiang, P., Watanabe, A., LoBello, J., Sima, C., Hostetter, G., Shepard, H. M., Von Hoff, D. D., & Han, H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1051 · Cited by 645
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622
Roles of heparan-sulphate glycosaminoglycans in cancer
Sasisekharan, R., Shriver, Z., Venkataraman, G., & Narayanasami, U. (2002) · Nature Reviews Cancer · doi:10.1038/nrc842 · Cited by 621
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Self-citationRecent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591 · cited 1×
“Several mechanisms of resistance to antiangiogenic therapy have been proposed thus far (9, 33).”
BackgroundAuvinen, P., Tammi, R., Parkkinen, J., Tammi, M., Ågren, U., Johansson, R., Hirvikoski, P., Eskelinen, M., & Kosma, V.-M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64757-8 · Cited by 493
Stylianopoulos, T., Martin, J. D., Snuderl, M., Mpekris, F., Jain, S. R., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4521 · Cited by 477
Self-citationChen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451 · cited 1×
“In line with these data, we also found an increased recruitment of immunosuppressive MDSCs after anti-VEGF therapy (41, 42).”
BackgroundSelf-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citationAngiotensin II Type 1a Receptor-deficient Mice with Hypotension and Hyperreninemia
Sugaya, T., Nishimatsu, S.-I., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18719 · Cited by 366
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346 · cited 1×
“1 [a VEGF-blocking antibody abbreviated as B20 from here onward (19)] significantly prolonged survival of mice bearing liver metastatic SL4 tumors (median survival, 14.”
BackgroundKosaki, R., Watanabe, K., & Yamaguchi, Y. (1999) · PubMed · Cited by 335
Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S. A., Gladkov, O. A., Holcombe, R. F., Korn, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 333 · cited 2×
“On the basis of recent reports, HA depletion appeared more effective in patients with tumors with high baseline amounts of HA (70).”
BackgroundGhatak, S., Misra, S., & Toole, B. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202404200 · Cited by 332
Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.
Ropponen, K. M., Tammi, M., Parkkinen, J. J., Eskelinen, M., Tammi, R., Lipponen, P., Ågren, U. M., ALHAVA, E. M., & Kosma, V. (1998) · PubMed · Cited by 327
Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo
Tannous, B. A. (2009) · Nature Protocols · doi:10.1038/nprot.2009.28 · Cited by 303 · cited 1×
“Tumor burden was assessed bymeasuring blood concentration ofGaussia luciferase (Gluc) fromGluc-transduced tumors (73, 74) or using a highfrequency ultrasound imaging system (VisualSonics).”
MethodEnzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298 · cited 1×
“Our recent studies showed that HA impairs vascular function and drug delivery into the tumor in animal models of pancreatic and prostate cancers (12, 15, 43, 44).”
BackgroundHyaluronan in human malignancies
Sironen, R. K., Tammi, M., Tammi, R., Auvinen, P. K., Anttila, M., & Kosma, V.-M. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.017 · Cited by 294
Tammi, R. H., Kultti, A., Kosma, V.-M., Pirinen, R., Auvinen, P., & Tammi, M. I. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.005 · Cited by 272
Bourguignon, L. Y. W., Gunja-Smith, Z., Iida, N., Zhu, H. B., Young, L. J. T., Muller, W. J., & Cardiff, R. D. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199807)176:1<206::aid-jcp22>3.0.co;2-3 · Cited by 270
Yu, Q., Toole, B. P., & Stamenkovic, I. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.1985 · Cited by 250
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V, Deschoemaeker, S., & Mazzone, M. (2014) · Oncogene · doi:10.1038/onc.2013.121 · Cited by 243
Hall, C. L., Wang, C., Lange, L. A., & Turley, E. A. (1994) · The Journal of cell biology · doi:10.1083/jcb.126.2.575 · Cited by 231 · cited 1×
“Interaction of HA with its specific cell surface receptors CD44 and RHAMM (receptor for HA-mediated motility) mediates evasion of apoptosis, particularly in anchorageindependent conditions (59–61), which might be explained by activation of several signaling cascades such as the phosphatidylinositol 3-kinase (PI3K)/AKT…”
BackgroundTargeting the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a Second Look
Whatcott, C. J., Han, H., Posner, R. G., Hostetter, G., & Von Hoff, D. D. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0136 · Cited by 223
Elevated Hyaluronan Production Induces Mesenchymal and Transformed Properties in Epithelial Cells
Zoltan-Jones, A., Huang, L., Ghatak, S., & Toole, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308168200 · Cited by 219
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211 · cited 2×
“Hypoxia drives HA expression in colorectal liver metastases after anti-VEGF therapy Previous studies have shown that increased collagen deposition after antiVEGF therapy is related to tumor hypoxia (10, 11).”
BackgroundSelf-citationItano, N., Sawai, T., Miyaishi, O., & Kimata, K. (1999) · PubMed · Cited by 206
Chauhan, V. P., Boucher, Y., Ferrone, C. R., Roberge, S., Martin, J. D., Stylianopoulos, T., Bardeesy, N., DePinho, R. A., Padera, T. P., Munn, L. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.003 · Cited by 204
Self-citationTwo-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
Alexandrakis, G., Brown, E. B., Tong, R. T., McKee, T. D., Campbell, R. B., Boucher, Y., & Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm981 · Cited by 178
Self-citationLipponen, P., Aaltomaa, S., Tammi, R., Tammi, M., Ågren, U., & Kosma, V.-M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00448-2 · Cited by 168
Pirinen, R., Tammi, R., Tammi, M., Hirvikoski, P., Parkkinen, J. J., Johansson, R., B�hm, J., Hollm�n, S., & Kosma, V.-M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<12::aid-ijc1002>3.0.co;2-e · Cited by 147
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Singha, N. C., Nekoroski, T., Zhao, C., Symons, R., Jiang, P., Frost, G. I., Huang, Z., & Shepard, H. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0580 · Cited by 144
Thorne, R. G., Lakkaraju, A., Rodriguez-Boulan, E., & Nicholson, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711345105 · Cited by 135
A colon tumor model for anticancer agent evaluation
Griswold, D. P., & Corbett, T. H. (2006) · Cancer · doi:10.1002/1097-0142(197512)36:6<2441::aid-cncr2820360627>3.0.co;2-p · Cited by 129 · cited 1×
“Anti-VEGF therapy alters mechanical properties of murine CRC liver metastasis Next, to investigate the mechanisms and consequences of increased HA expression after VEGF-targeted therapy, we used two syngeneic mouse models of liver mCRC (SL4 andCT26) (17, 18).”
MethodHyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers.
Wang, C., Tammi, M., Guo, H., & Tammi, R. (1996) · Europe PMC (PubMed Central) · Cited by 127
Koochekpour, S., Pilkington, G. J., & Merzak, A. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630325 · Cited by 112
CD44 signaling through focal adhesion kinase and its anti‐apoptotic effect
Fujita, Y., Kitagawa, M., Nakamura, S., Azuma, K., Ishii, G., Higashi, M., Kishi, H., Hiwasa, T., Koda, K., Nakajima, N., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03262-3 · Cited by 112
Therapeutic Targeting of Hyaluronan in the Tumor Stroma
Kultti, A., Li, X., Jiang, P., Thompson, C. B., Frost, G. I., & Shepard, H. M. (2012) · Cancers · doi:10.3390/cancers4030873 · Cited by 105
Chung, E., Yamashita, H., Au, P., Tannous, B. A., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008316 · Cited by 100 · cited 1×
“Tumor burden was assessed bymeasuring blood concentration ofGaussia luciferase (Gluc) fromGluc-transduced tumors (73, 74) or using a highfrequency ultrasound imaging system (VisualSonics).”
MethodSelf-citationAguilera, K. Y., Rivera, L. B., Hur, H., Carbon, J. G., Toombs, J. E., Goldstein, C. D., Dellinger, M. T., Castrillon, D. H., & Brekken, R. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2800 · Cited by 100
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
Strickler, J. H., & Hurwitz, H. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0003 · Cited by 96 · cited 1×
“Because antiVEGF therapy is commonly administered together with systemic chemotherapy in mCRC patients (32), and given the effects of HA depletion on perfusion of liver mCRCs treated with anti-VEGF therapy in mice, we next examined the effect of adding chemotherapy to antiVEGF therapy and PEG-HAse.”
BackgroundTAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis
Kamarashev, J. A., Ferrone, S., Seifert, B., B�ni, R., Nestle, F. O., Burg, G., & Dummer, R. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<73::aid-ijc1013>3.0.co;2-s · Cited by 79
Wicherts, D. A., de Haas, R. J., Sebagh, M., Corrales, E. S., Gorden, D. L., Lévi, F., Paule, B., Azoulay, D., Castaing, D., & Adam, R. A. (2010) · British journal of surgery · doi:10.1002/bjs.7368 · Cited by 57 · cited 1×
“3C), a finding consistent with the data from patients with liver mCRCs after preoperative chemotherapy with and without bevacizumab (20).”
ResultMorimoto‐Tomita, M., Ohashi, Y., Matsubara, A., Tsuiji, M., & Irimura, T. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-3585-0 · Cited by 44
Myeloid Cells as Targets for Therapy in Solid Tumors
Cotechini, T., Medler, T. R., & Coussens, L. M. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000132 · Cited by 39
Effect of sulfated glycosaminoglycans on tumor invasion and metastasis
Eliene, O. K. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/244 · Cited by 17
Research works printed but not linked: 1
- 10.1056/NEJM198612253152606 · DOI · Paper page
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationExtracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 855
“Stiffening promotes tumor progression in many tumor types, including breast (80, 90), pancreatic (85, 91), colorectal (92), andbrain (93).”
BackgroundSelf-citationThe role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
“It seems that reduction of the amount of HA accumulated in the core of ECM stiffness could be a beneficial strategy for decreasing physical obstacles to systemic chemotherapy for patients with cancer.(27) Stiffness‐mediated drug impedance is carried out through directing multiple ways.”
Background
Metadata
- Authors
- Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., Heishi, T., Martin, J. D., Huang, Y., Maimon, N., Reissfelder, C., Weitz, J., Boucher, Y., Clark, J. W., Grodzinsky, A. J., Duda, D. G., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- University Hospital Carl Gustav Carus (DE)
- Department of General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany.
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- Fukumura, Dai
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-10-12
- Volume
- 8
- Issue
- 360
- Pages
- 360ra135-360ra135
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5457741
- OpenAlex
- W2530012709
- Cited by
- 258
- References
- 78
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 24 · 2023: 28 · 2022: 37 · 2021: 40 · 2020: 30 · 2019: 21 · 2018: 19 · 2017: 16 · 2016: 3
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- NIH (CA080124, T32DK007191, CA126642, CA197743, CA096915, CA139168, CA159258, CA098706, CA173518)
- American Cancer Society (120733-RSG-11-073-01-TBG)
- German Research Foundation
- Foundation for Science and Technology
- Portuguese Human Potential Operational Program/European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anti-VEGF therapy, colorectal liver metastases, extracellular matrix remodeling, hyaluronic acid, sulfated glycosaminoglycans, tumor stiffness, tumor hypoxia, bevacizumab, acquired drug resistance, tumor perfusion, combination chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Animals, Hypoxia, Biomechanical Phenomena, Extracellular Matrix, Glycosaminoglycans, Humans, Hyaluronic Acid, Liver Neoplasms, Mice, Inbred BALB C, Mice, Inbred C57BL, Colorectal Neoplasms, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.